

PREDICTIVE METHODS

BASED ON ALPHA-1-ACID GLYCOPROTEIN LEVELS

Abstract of the Invention

A method for determining the dosage of a taxoid to  
5 administer to a patient who is being treated for cancer and  
whose body fluids include alpha-1-acid glycoprotein  
comprising observing the patient's level of alpha-1-acid  
glycoprotein, evaluating said level to determine the dosage  
of the taxoid to administer to the patient by comparing said  
10 level to a predetermined alpha-1-acid glycoprotein level  
derived from a population of patients having said cancer and  
treated with said taxoid at a common dosage and based on said  
evaluation, recommending the dosage of the taxoid to  
administer to the patient. Also, a method for assessing the  
15 effect of treatment of a patient who has cancer and who is  
being treated with a taxoid comprising observing the  
patient's alpha-1-acid glycoprotein level, comparing said  
level to a predetermined alpha-1-acid glycoprotein level  
derived from a population of patients having said cancer and  
20 treated with said taxoid at a common dosage and based on said  
comparison, assessing the effect of continued treatment of  
the patient with respect to the patient's response to  
treatment, the length of survival of the patient, or side  
effects that may be experienced by the patient. Also, a  
25 method for reducing the side effects experienced by a patient  
who has cancer and who is to be treated with a taxoid  
comprising observing the patient's alpha-1-acid glycoprotein  
(AAG) level, comparing said level to a predetermined alpha-1-  
acid glycoprotein level derived from a population of patients  
30 having said cancer and treated with said taxoid at a common  
dosage and based on said comparison recommending the dosage  
of said taxoid to administer to said patient to reduce the  
incidence or severity of side effects that the patient may  
experience during treatment with said taxoid.